(redirected from Tenofovir disoproxil fumarate)
Also found in: Medical.
Related to Tenofovir disoproxil fumarate: emtricitabine


An antiviral drug, C9H14N5O4P, used in the form of a prodrug (tenofovir disoproxil fumarate) to treat chronic hepatitis B and, in combination with other drugs, to treat HIV infection or to reduce the risk of HIV infection.

[teno-, of unknown origin + fo- (alteration of pho(spho)-) + (anti)vir(al).]


n tenofovir m
Mentioned in ?
References in periodicals archive ?
Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and tenofovir disoproxil fumarate.
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
The combination of dolutegravir plus fixed-dose tenofovir disoproxil fumarate and emtricitabine is administered as 2 pills per day.
HIV-infected patients with hepatitis B virus (HBV) coinfection should initiate a recommended ART regimen that contains tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), lamivudine or emtricitabine, and a third component.
Liu of the San Francisco Department of Public Health, adding that previous work in this field--namely, the 2010 iPrEx (Pre-Exposure Prophylaxis Initiative) trial--found that tenofovir disoproxil fumarate and emtricitabine led to an overall 44% reduction in HIV acquisition among the aforementioned demographic groups.
The daily regimen containing emtricitabine, tenofovir disoproxil fumarate, and rilpivirine HCl is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients (Figure 1) [2].
World Health Organization guidelines recommend Emtricitabine, as well as Tenofovir Disoproxil Fumarate (TDF), as preferred components of first- and second-line HIV therapy.
The products include atazanavir capsule, 300 mg, ritonavir tablet, 100 mg (heat-stable) and tenofovir disoproxil fumarate and lamivudine tablet 300 mg/300 mg, or "second-line-in-a-box"; fixed-dose combination atazanavir sulfate and ritonavir tablets, 300 mg/100 mg; and fixed-dose combination abacavir sulfate, lamivudine and zidovudine tablets, 300 mg/150 mg/300 mg.
On May 1, 2001, Gilead Sciences announced the submittal of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of tenofovir disoproxil fumarate (tenofovir DF).
On October 26 the FDA approved Viread (tm) -- generic name tenofovir disoproxil fumarate, or tenofovir DF.